Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

Herbert S.  Schwartz

Herbert S. Schwartz, M.D.

Orthopaedics Chair
Professor and Chair, Department of Orthopaedic Surgery and Rehabilitation
Professor of Pathology, Microbiology and Immunology
Orthopaedic Oncologist

  • Appointments
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
  • Faxes
    Office Fax
    Clinic Fax
  • Addresses
    Vanderbilt Orthopaedic Institute
    Medical Center East, South Tower, Suite 4200
    Nashville, TN 37232-8774

    Vanderbilt Orthopaedic Institute
    Medical Center East, South Tower, Suite 4200
    Nashville, TN 37232-8774

Dr. Schwartz has been at Vanderbilt since 1987 and is currently the most senior and experienced full-time academic orthopaedic oncologist in the mid-southern United States. There are only approximately 50 such specialists in the country. Referrals from all over the United States and foreign countries are commonly seen in oncology clinic. Dr. Schwartz is married and has three children (one boy and two girls). His hobbies include: running, baseball, and spending time with his family.

  • Vanderbilt University - Post Doc - Molecular Genetics
  • Mayo Clinic - Fellowship - Musculoskeletal Oncology
  • University of Chicago - Residency - Orthopaedic Surgery
  • University of Chicago - Medical School - MD
  • University of Illinois -Chicago - BS Biology
Research Specialty

Coagulation biology of sarcomas, Proteomics of sarcomas, bone metastasis, metabolic bone disease and tissue engineering.

Clinical Interest

Limb-salvage surgery (avoiding amputation), limb-girdle and complex pelvic surgery are areas of special focus. The treatment of metastatic bone cancer from carcinomas and melanomas are other areas of interest and expertise.

Clinical Research Description

A comprehensive orthopaedic oncology unit is involved in both clinical and basic science research concerned with sarcomas and other neoplasms. Participation in multi-institutional cancer protocols are underway for osteosarcoma and Ewing's sarcoma, and soft tissue sarcomas.